Jacqueline Barrientos, MD from Northwell Health, New York, NY discuss a placebo-controlled study of idelalisib in combination with bendamustine plus rituximab, also known as BR (NCT01569295). The results after a longer follow-up showed a median progression free survival (PFS) of 23 months while patients with 17p deletions had a PFS of 16 months. Dr Barrientos continues to discuss why this difference in PFS may have arisen, either because of a higher rate of discontinuation of therapy in 17p del patients due to side effects or due to chromosome instability leading to resistance. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib
